Phyto Medicines Profile
Key Indicators
- Authorised Capital ₹ 9.80 M
as on 13-12-2024
- Paid Up Capital ₹ 2.72 M
as on 13-12-2024
- Company Age 35 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2020)
- Profit -101.96%
(FY 2020)
- Ebitda -101.96%
(FY 2020)
- Net Worth -64.40%
(FY 2020)
- Total Assets -50.53%
(FY 2020)
About Phyto Medicines
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 9.80 M and a paid-up capital of Rs 2.72 M, as per Ministry of Corporate Affairs (MCA) records.
Murari Murarka, Rita Murarka, and Radheshyam Saha serve as directors at the Company.
- CIN/LLPIN
U24231WB1989PLC046768
- Company No.
046768
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
25 Apr 1989
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Phyto Medicines?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Murari Murarka  | Director | 25-Apr-1989 | Current |
| Rita Murarka | Director | 03-Sep-2018 | Current |
| Radheshyam Saha | Director | 28-Sep-2007 | Current |
Financial Performance of Phyto Medicines.
Phyto Medicines Ltd., for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 101.96% decrease in profit. The company's net worth observed a substantial decline by a decrease of 64.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Phyto Medicines?
In 2019, Phyto Medicines had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pashupati Chemicals & Pharmaceuticals LimitedActive 40 years 8 monthsMurari Murarka, Rita Murarka and 1 more are mutual person
Psl Financial Services Ltd.Active 35 years 11 monthsMurari Murarka and Rita Murarka are mutual person
- Saffy Healthcare Private LimitedActive 36 years 5 months
Murari Murarka and Rita Murarka are mutual person
- Pashupati Promoters LimitedActive 35 years 4 months
Murari Murarka, Rita Murarka and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Phyto Medicines?
Unlock and access historical data on people associated with Phyto Medicines, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Phyto Medicines, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Phyto Medicines's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
